Jasper Therapeutics
(NASDAQ) JSPR
Jasper Therapeutics Financials at a Glance
Market Cap
$25.19M
Revenue (TTM)
$0.00
Net Income (TTM)
$66.70M
EPS (TTM)
$-5.90
P/E Ratio
-0.15
Dividend
$0.00
Beta (Volatility)
0.93 (Low)
Dividend
$0.00
Beta (Volatility)
0.93 (Low)
Price
$0.87
Volume
14,338
Open
$0.91
Price
$0.87
Volume
14,338
Open
$0.91
Previous Close
$0.87
Daily Range
$0.82 - $0.91
52-Week Range
$0.81 - $7.19
Dividend
$0.00
Beta (Volatility)
0.93 (Low)
Price
$0.87
Volume
14,338
Open
$0.91
Previous Close
$0.87
Daily Range
$0.82 - $0.91
52-Week Range
$0.81 - $7.19
JSPR News
JSPR: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Jasper Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
22
CEO
Ronald A. Martell
Website
www.jaspertherapeutics.comHeadquarters
Redwood City, CA 94065, US
JSPR Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-191%
Return on Capital
-4%
Return on Assets
-2%
Earnings Yield
-6.67%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$25.19M
Shares Outstanding
27.98M
Volume
14.34K
Short Interest
0.00%
Avg. Volume
595.90K
Financials (TTM)
Gross Profit
$0.00
Operating Income
$83.88M
EBITDA
$83.88M
Operating Cash Flow
$77.16M
Capital Expenditure
$7.00K
Free Cash Flow
$77.17M
Cash & ST Invst.
$28.69M
Total Debt
$1.24M
Jasper Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
$25.19M
N/A
Market Cap/Employee
$393.52K
N/A
Employees
64
N/A
Net Income
$0.00
+100.0%
EBITDA
$15.84M
+36.7%
Quarterly Fundamentals
Net Cash
$27.46M
-60.7%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$1.24M
+13.4%
Return on Assets
-1.86%
N/A
Return on Invested Capital
-3.72%
N/A
Free Cash Flow
$614.12K
+102.9%
Operating Cash Flow
$614.12K
+102.9%